NCT05855382Completed
Prevalence of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region
A Prevalence Study of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Recent studies suggest that up to 80% of survivors may develop chronic multi-organ dysfunction due to persistent inflammation and immune dysregulation, making it an ongoing public health concern worldwide. The study aims to (1) describe and establish the frequency of physical and psychological signs and symptoms in adult patients who have tested positive for COVID-19, (2) identify individuals who meet the WHO case definition of Persistent COVID-19 in Chile, (3) explore risk factors associated with persistent COVID-19 to guide intervention strategies, and (4) explore inflammatory and molecular biomarkers associated with persistent COVID-19. The research project utilizes a stratified random sampling with a mixed-methods embedded design. In the first phase, individuals diagnosed with COVID-19 will be recruited and followed up to complete the study's sample universe. A sociodemographic survey, blood sampling (including complete blood count, biochemical profile, immunoglobulin mutational status analysis, and analysis of inflammatory biomarkers), and a battery of psychological tests will be administered. In the second phase, kinesiology studies and medical consultation and evaluation will be conducted to determine if individuals have Persistent COVID-19 and to derive them to the healthcare network. In the final follow-up phase, participants diagnosed with Persistent COVID-19 will be invited to undergo musculoskeletal and respiratory assessments to complete the diagnosis of symptoms associated with the pathology.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 282 (actual)
- First submitted
- 7 May 2023
- Start date
- 15 May 2023
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Universidad de Magallanes
- NCT number
- NCT05855382
What you commit to
- Study type: Observational
- Participants enrolled: 282
- From 15 May 2023 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any physical, mental, immunosuppressive, or social condition that, in the investigator's judgment, might interfere with the completion of the baseline assessments and evaluations.
Age
- Age \< 18 years
Other
- Individuals who are digitally illiterate and do not have access to nearby networks to support them during the process.
Who the study is looking for
- Age ≥ 18 years
- Individuals must be included in the COVID-19 monitoring database by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
- Patients able to give informed consent.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Teaching and Research Healthcare Center of the University of Magallanes (CADI-UMAG) Coordinator of this site? Confirm its status | Punta Arenas | Chile | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.